[go: up one dir, main page]

PT808163E - Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada - Google Patents

Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada

Info

Publication number
PT808163E
PT808163E PT96903540T PT96903540T PT808163E PT 808163 E PT808163 E PT 808163E PT 96903540 T PT96903540 T PT 96903540T PT 96903540 T PT96903540 T PT 96903540T PT 808163 E PT808163 E PT 808163E
Authority
PT
Portugal
Prior art keywords
reversal
formation
advanced
advanced glycosylation
protein
Prior art date
Application number
PT96903540T
Other languages
English (en)
Inventor
Anthony Cerami
Peter C Ulrich
Sara Vasan
John J Egan
Dilip R Wagle
San-Bao Hwang
Original Assignee
Alteon Inc
Picower Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/375,155 external-priority patent/US5656261A/en
Application filed by Alteon Inc, Picower Inst Med Res filed Critical Alteon Inc
Publication of PT808163E publication Critical patent/PT808163E/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
PT96903540T 1995-01-18 1996-01-18 Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada PT808163E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/375,155 US5656261A (en) 1995-01-18 1995-01-18 Preventing and reversing advanced glycosylation endproducts
US08/588,249 US5853703A (en) 1995-01-18 1996-01-18 Preventing and reversing the formation of advanced glycosylation endproducts

Publications (1)

Publication Number Publication Date
PT808163E true PT808163E (pt) 2003-12-31

Family

ID=27006923

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96903540T PT808163E (pt) 1995-01-18 1996-01-18 Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada

Country Status (14)

Country Link
US (1) US5853703A (pt)
EP (2) EP0808163B1 (pt)
JP (1) JP4067562B2 (pt)
CN (1) CN1142778C (pt)
AT (1) ATE245420T1 (pt)
BR (1) BR9607598B1 (pt)
CA (1) CA2210684C (pt)
DE (1) DE69629176T2 (pt)
DK (1) DK0808163T3 (pt)
ES (1) ES2203677T3 (pt)
MX (1) MX9705449A (pt)
NZ (1) NZ302027A (pt)
PT (1) PT808163E (pt)
WO (1) WO1996022095A2 (pt)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO315930B1 (no) * 1995-01-18 2003-11-17 Picower Inst For Medical Res T Anvendelse av tiazoliumforbindelser ved fremstilling av farmasöytiske preparater, preparater som inneholder forbindelsene, samt nyetiazoliumforbindelser
US5656261A (en) 1995-01-18 1997-08-12 The Picower Institute For Medical Research Preventing and reversing advanced glycosylation endproducts
JP2000507346A (ja) * 1995-12-26 2000-06-13 ザ ピコワー インスティテュート フォア メディカル リサーチ タバコ及びその燃焼副産物中の高次糖付加最終生成物の存在を基にする測定方法及び治療方法
US20040198795A1 (en) * 1996-05-08 2004-10-07 Wagle Dilip R Substituted imidazoliums and methods of use therefor
US6119701A (en) * 1998-02-13 2000-09-19 Cerami Consulting Corp. Methods, agents and devices for removing nucleophilic toxins from tobacco and tobacco smoke
US6121300A (en) * 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
AU769940B2 (en) * 1999-10-06 2004-02-12 Torrent Pharmaceuticals Ltd Pyridinium derivatives for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
US20020103228A1 (en) * 1999-10-06 2002-08-01 Torrent Pharmaceuticals Ltd. Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications
CZ20011808A3 (cs) * 1999-10-06 2001-08-15 Torrent Pharmaceuticals Ltd Sloučenina pyridiniové řady, způsob její výroby a jejího použití, farmaceutický přípravek ji obsahující a jeho použití
US6608094B2 (en) 1999-10-06 2003-08-19 Torrent Pharmaceuticals Ltd. Compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
ES2287096T3 (es) * 2000-01-19 2007-12-16 Synvista Therapeutics, Inc. Compuestos de tiazol, imidazol y oxazol y tratamientos de trastornos asociados con el envejecimiento de las proteinas.
WO2001062250A1 (en) * 2000-02-23 2001-08-30 Alteon, Inc. Thiazolium compounds and treatments of disorders associated with protein aging
AU2001249683A1 (en) * 2000-03-29 2001-10-08 Alteon Inc. Synthesis of thiazolium compounds
US7439330B2 (en) * 2000-05-08 2008-10-21 President And Fellows Of Harvard College Anti-glycated CD59 antibodies and uses thereof
US6835545B2 (en) * 2000-05-08 2004-12-28 President And Fellows Of Harvard College Methods, products and treatments for diabetes
ES2251500T3 (es) * 2000-07-13 2006-05-01 Alteon, Inc. Tiazolios e imidazolios sustituidos por cianometilo y tratamientos de desordenes asociados al envejecimiento proteinico.
JP2004525904A (ja) * 2000-12-29 2004-08-26 アルテオン インコーポレイテッド 線維性疾患又は他の適応症ｉｉｉｃの治療方法
EP1353676A4 (en) * 2000-12-29 2006-05-31 Alteon Inc METHOD FOR THE TREATMENT OF FIBROUS OR OTHER INDICATIONS
DE60130030T2 (de) * 2000-12-29 2008-04-30 Alteon Inc. Verfahren zur behandlung von glaukom
WO2002056836A2 (en) * 2001-01-22 2002-07-25 Farrington Pharmaceuticals, Llc Method and composition for rejuvenating hair, nails, tissues, cells and organs by ex-vivo or immersive treatment
ES2243389T3 (es) * 2001-03-21 2005-12-01 Torrent Pharmaceuticals Ltd Compuestos de piridinio utiles para el tratamiento de enfermedades relacionadas con los age.
CZ303214B6 (cs) * 2001-03-21 2012-05-30 Torrent Pharmaceuticals Ltd Pyridiniová sloucenina, zpusob její výroby, její použití, farmaceutický prostredek ji obsahující, zpusob jeho výroby a jeho použití
AU766824B2 (en) * 2001-03-28 2003-10-23 Torrent Pharmaceuticals Ltd Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses
MXPA03008089A (es) 2001-04-05 2004-01-22 Torrent Pharmaceuticals Ltd Compuestos heterociclicos para complicaciones relacionadas con el envejecimiento y vasculares diabeticas.
CA2448294A1 (en) * 2001-05-30 2002-12-05 Alteon Inc. Method for treating fibrotic diseases or other indications vi
US20030027820A1 (en) * 2001-05-30 2003-02-06 Alteon, Inc. Method for treating fibrotic diseases or other indications V
JP2004536807A (ja) * 2001-05-30 2004-12-09 アルテオン インコーポレイテッド 緑内障ｖの治療方法
CA2495966A1 (en) * 2002-05-23 2003-12-04 Thomas J. Maniscalco Sunscreen compositions and methods of use thereof
US7144570B2 (en) * 2002-05-23 2006-12-05 Alteon, Inc. Sunscreen compositions and methods of use thereof
DE10225537A1 (de) * 2002-06-10 2003-12-18 Bayer Ag N-alkylierte Thiazoliumsalze und Verfahren zu deren Herstellung
EP1575513A4 (en) * 2002-08-16 2007-04-04 Wyeth Corp COMPOSITIONS AND METHODS FOR TREATING RAGE-ASSOCIATED DISEASES
US6991488B2 (en) 2002-09-25 2006-01-31 Anthony Freakes Electrical connector devices and methods for employing same
WO2004058289A1 (en) * 2002-12-20 2004-07-15 Chakshu Research, Inc. Ophthalmic formulation for the prevention and treatment of ocular conditions
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
CN1324019C (zh) * 2003-04-02 2007-07-04 深圳市东阳光实业发展有限公司 氮杂双环盐类化合物及其治疗蛋白老化疾病的用途
US20050014747A1 (en) * 2003-04-18 2005-01-20 Emily Reinhard Dihydrothiazine prodrugs of thiazolium agents
US7416756B2 (en) 2003-09-10 2008-08-26 Eastman Chemical Company Process for the recovery of a phytolipid composition
US20050137239A1 (en) * 2003-12-17 2005-06-23 Hines Michelle D. Thiazole derivatives
US8119651B2 (en) * 2004-01-30 2012-02-21 Biotie Therapies Corp. Compositions useful especially for treatment or prevention of metabolic syndrome
FI20060768A0 (fi) * 2006-08-28 2006-08-28 Faron Pharmaceuticals Oy Erityisesti metabolia-oireyhtymän hoitoon tai ehkäisyyn soveltuvia koostumuksia
WO2006017563A2 (en) * 2004-08-02 2006-02-16 The Trustees Of Columbia University In The City Of New York Compositions and methods for reversing age-related changes in extracellular matrix proteins
AU2005271452B2 (en) 2004-08-03 2011-11-03 Vtv Therapeutics Llc RAGE fusion proteins and methods of use
EA012586B1 (ru) * 2004-08-03 2009-10-30 Транстек Фарма, Инк. Rage-слитые белки и способы их применения
WO2006032165A1 (fr) * 2004-09-23 2006-03-30 Beijing Molecule Science And Technology Co., Ltd Nouveaux composés n-hétérocycliques substitués à cinq chaînons, et utilisation desdits composés dans le traitement des maladies liées au vieillissement des protéines
WO2006034605A1 (fr) * 2004-09-28 2006-04-06 Beijing Molecule Science And Technology Co., Ltd. Nouveaux ammoniums a noyaux azabicycliques et leur utilisation pour le traitement des troubles lies au vieillissement des proteines
WO2006086098A2 (en) 2005-01-06 2006-08-17 President And Fellows Of Harvard College Mass spectrometric methods and products
US20070098709A1 (en) * 2005-06-29 2007-05-03 Gaetano Barile Methods for treating and preventing diabetic retinopathy
EP1907006A2 (en) * 2005-07-15 2008-04-09 Chakshu Research, Inc. Prevention and treatment of ophthalmic complications of diabetes
US7569210B2 (en) * 2005-09-26 2009-08-04 Jamie Collins Doss Therapeutic soap product with UV protection
CA2634908C (en) * 2005-12-23 2015-05-19 Gcoder Systems Ab Positioning pattern
CN101007789B (zh) * 2006-01-27 2014-08-20 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
CN104151261B (zh) * 2006-01-27 2017-02-15 北京摩力克科技有限公司 取代五元氮杂环盐类化合物及其治疗蛋白老化相关疾病的用途
EA015657B1 (ru) * 2006-02-09 2011-10-31 Транстек Фарма, Инк. Слитые белки rage и способы применения
AU2007248784B2 (en) * 2006-05-05 2013-11-21 Vtv Therapeutics Llc RAGE fusion proteins, formulations, and methods of use thereof
US20080199467A1 (en) * 2007-02-15 2008-08-21 Mjalli Adnan M M Immunoglobulin fusion proteins and methods of making
US8398977B2 (en) 2007-06-14 2013-03-19 Galactica Pharmaceuticals, Inc. Rage fusion proteins
WO2009023207A1 (en) * 2007-08-13 2009-02-19 Synvista Therapeutics, Inc. Thiazolium compounds for treating gastrointestinal complications
US20090088461A1 (en) * 2007-09-26 2009-04-02 Synvista Therapeutics, Inc. Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet
WO2009051804A1 (en) * 2007-10-18 2009-04-23 Synvista Therapeutics, Inc. Thiazolium compounds for treating or preventing diseases associated with insulin resistance
CN101684106B (zh) * 2008-09-22 2013-06-12 北京摩力克科技有限公司 噻唑鎓盐类化合物及其治疗蛋白老化相关疾病的用途
EP2421892A1 (en) 2009-04-20 2012-02-29 Pfizer Inc. Control of protein glycosylation and compositions and methods relating thereto
EP2427432A2 (en) 2009-05-07 2012-03-14 Torrent Pharmaceuticals Limited Novel heterocyclic compounds
FR2951085B1 (fr) 2009-10-09 2012-05-18 Inst Substances Vegetales Utilisation de composes phenoliques pour la deglycation des proteines
WO2012027555A2 (en) 2010-08-25 2012-03-01 President And Fellows Of Harvard College Glycated cd59 peptides, their preparation, and uses thereof
US9622469B2 (en) 2013-10-03 2017-04-18 David Spiegel Crosslink breakers for preservation of biological substances
CN106187935A (zh) * 2016-07-04 2016-12-07 蚌埠学院 一种3‑苯甲基‑5‑（2‑羟乙基）‑4‑甲基噻唑啉氯的合成方法
CN112028833B (zh) * 2020-09-25 2022-07-05 西南大学 对氨基水杨酸唑类衍生物及其制备方法和应用
CN112094279B (zh) * 2020-09-25 2022-11-18 西南大学 对氨基水杨酸双氢青蒿素类衍生物及其制备方法和应用
WO2024062164A1 (fr) 2022-09-23 2024-03-28 A2P Sciences Acide sagerinique et compositions le contenant pour utilisation dans la prevention et/ou le traitement des troubles lies a la senescence chez un etre humain ou animal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1364779A (en) * 1972-05-09 1974-08-29 Soc D Etudes Prod Chimique Thiazole derivative
JPS60184038A (ja) * 1984-03-01 1985-09-19 Nippon Kasei Kk １−ヒドロキシ−２−オン類の製造方法
US5262152A (en) * 1984-03-19 1993-11-16 The Rockefeller University Amidrazones and derivatives thereof
US5869534A (en) * 1992-05-21 1999-02-09 The Picower Institute For Medical Research Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
US5399560A (en) * 1984-03-19 1995-03-21 The Rockefeller University 1,2,4-triazine products resulting from the inhibition of advanced glycosylation
CA1273011A (en) * 1984-07-02 1990-08-21 Susan M. Schmitt Carbapenems having an externally alkylated mono- or bicyclic 2-quaternary heteroarylalkylthio substituent
DE3428483C1 (de) * 1984-08-02 1985-06-20 Zündwarenfabrik Starcke GmbH & Co, 4520 Melle Springrollo
US4609670A (en) * 1984-11-13 1986-09-02 Eli Lilly And Company Imidazolium hypoglycemic agents
US4683312A (en) * 1984-11-13 1987-07-28 Eli Lilly And Company Imidazolium hypoglycemic agents
JP2507764B2 (ja) * 1987-11-30 1996-06-19 三井石油化学工業株式会社 低級アルキルスルフアモイルアミン類、その塩およびその用途
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US5108930A (en) * 1990-02-20 1992-04-28 Alteon Inc. Aminoguanidine assay and applications thereof
US5230998A (en) * 1991-07-25 1993-07-27 Neurath Alexander R Method for the prescreening of drugs targeted to the V3 hypervariable loop of the HIV-1 envelope glycoprotein gp 120
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5366885A (en) * 1992-06-09 1994-11-22 Barranco Iii Sam C Method and kit for testing tumors for drug sensitivity
DE4222980A1 (de) * 1992-07-13 1994-01-20 Cassella Ag Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten
CA2120248A1 (en) * 1992-07-30 1994-02-17 Toyoaki Ishikura Compounds which can be retained in brain

Also Published As

Publication number Publication date
EP0808163B1 (en) 2003-07-23
CA2210684C (en) 2008-01-15
ATE245420T1 (de) 2003-08-15
DE69629176T2 (de) 2004-06-03
WO1996022095A3 (en) 1997-02-27
BR9607598B1 (pt) 2009-05-05
WO1996022095A2 (en) 1996-07-25
CN1142778C (zh) 2004-03-24
JPH10512864A (ja) 1998-12-08
CA2210684A1 (en) 1996-07-25
CN1185736A (zh) 1998-06-24
MX9705449A (es) 1998-02-28
BR9607598A (pt) 1999-11-30
ES2203677T3 (es) 2004-04-16
NZ302027A (en) 2001-04-27
JP4067562B2 (ja) 2008-03-26
DK0808163T3 (da) 2003-11-10
EP1327887A2 (en) 2003-07-16
US5853703A (en) 1998-12-29
EP0808163A2 (en) 1997-11-26
DE69629176D1 (de) 2003-08-28
EP1327887A3 (en) 2008-12-10

Similar Documents

Publication Publication Date Title
PT808163E (pt) Uso de compostos de tiazolio para prevencao e inversao da formacao de produtos finais com glicosilacao avancada
Sim et al. Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with α 2-macroglobulin
ATE388704T1 (de) Umkehrung der fortgeschrittenen glycosylierungsvernetzungen durch verwendung von heterozyklisch substituierten thiazoliumsalzen
DE3650080D1 (de) Verfahren und Mittel zur Hemmung des Proteinveraltens.
EP0316852A3 (en) Inhibitors of nonenzymatic cross-linking
Pringle The melecular weight of the undegraded polypeptide chain of yeast hexokinase
CA2128248A1 (en) Amino Acids Useful as Inhibitors of the Advanced Glycosylation of Proteins
DE60008509D1 (de) Neue hemmern von fortgeschrittenen glykosilierung-endprodukten
DE69425904D1 (de) Hautbräunungsmittel
RU94046295A (ru) L-аспартил-d- альфа -аминоалканоил-(s)-n-d-алкилбензиламиды, используемые в качестве искусственных подслащивающих агентов, пищевой состав, способ подслащивания пищевого состава
AUPN627595A0 (en) Diagnostics and treatments of periodontal disease
ES2095847T3 (es) Desnaturalizacion oxidativa de analitos proteicos.
ATE207205T1 (de) Verfahren zumm assay von endotoxin-konzentration
Georges et al. Chemical modification of charged amino acid moieties alters the electrophoretic mobilities of neurofilament subunits on SDS/polyacrylamide gels
WO1996021450A3 (en) Bis-[hydrazones]
AU2825897A (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
Von Zabern et al. Chain structure of cobra venom factor from Naja naja and Naja haje venom
EP0693552A3 (en) Analytical element, composition and method using a modified horseradish apo-peroxidase
Fujii et al. Aldehyde content and cross-linking of type III collagen
ES2191837T3 (es) Derivados de 1,2,4-triazina para la inhibicion de glicosilacion de proteinas.
IZUMI et al. Purification and characterization of α-toxin of Clostridium oedematiens type A
SUZUKI et al. Guinea pig plasma murinoglobulin. Purification and some properties
FI950044A0 (fi) Menetelmä proteiini C:n hajoamisen estämiseksi
WO1997042175B1 (en) Substituted imidazolium salts and their use for the inhibition of protein ageing
Custer PARTIAL CHARACTERIZATION OF AN INHIBITOR OF BACTERIAL SPORE OUTGROWTH THAT IS THERMALLY DERIVED FROM NITRITE AND THE FORMATION OF ANALOGOUS INHIBITORS FROM LACTOFERRIN OR TRANSFERRIN FRAGMENTS AND NITRITE.